A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis

Area of Science:

• Neurology
• Immunology
• Clinical Medicine

Background:

• Myasthenic crisis is a life-threatening complication of Myasthenia gravis, affecting a significant percentage of patients.
• Therapeutic apheresis, including plasma exchange (PE) and immunoadsorption (IA), is used to remove autoantibodies in myasthenic crisis.
• Controlled comparative data on the safety and efficacy of PE versus IA were lacking.

Purpose of the Study:

• To prospectively compare the clinical safety and efficacy of immunoadsorption (IA) versus plasma exchange (PE) in patients experiencing myasthenic crisis.

Main Methods:

• A prospective randomized controlled trial involving 19 patients with myasthenic crisis.
• Patients were randomized to receive either PE (n=10) or IA (n=9) in addition to standard drug treatment.
• Treatments involved 3-5 sessions over 7 days with a low plasma volume dosage (1.5 L plasma, 20-25 ml/kg).

Main Results:

• Both IA and PE groups showed equal improvement in Myasthenia scores by Day 14 post-treatment.
• Patients in both groups achieved a stable clinical status (Oosterhuis Classes 1 and 2).
• Significant reduction in acetylcholine receptor antibodies (AChRAb) was observed after each apheresis session, with fewer serious adverse events reported for IA (1 SAE) compared to PE (7 SAEs).

Conclusions:

• Immunoadsorption (IA) is as effective as plasma exchange (PE) for treating myasthenic crisis.
• A low-volume dosage of 3-5 apheresis sessions is sufficient for significant clinical improvement.
• IA offers a potentially safer alternative to PE due to a lower incidence of serious adverse events.